What Pasteur Institute does

The Pasteur Institute (Institut Pasteur) is a French non-profit biomedical research foundation founded in 1887 by Louis Pasteur and headquartered in Paris. It operates four core missions — research, public health, education, and innovation/technology transfer — specializing in infectious diseases, immunology, microbiology, genomics, and antimicrobial resistance. The institute runs 133 research units in Paris, maintains the Pasteur Network of over 30 member institutes across more than 20 countries, and houses a unique Collection de l'Institut Pasteur (CIP) with over 25,000 bacterial strains belonging to 5,500 species. Its research outputs include vaccine candidates (MV-CHIK for chikungunya), organ-on-chip microfluidic devices, AI-powered vector identification tools, and National Reference Centers providing surveillance for bacteria, viruses, fungi, and parasites.

The institute generates revenue from a diversified mix of sources: government and international research grants (including a €15.3M EDCTP3 grant for chikungunya vaccine work and a €30M allocation for a new mosquito-control research center), philanthropy (PasteurDon campaigns, Bettencourt Schueller Foundation), clinical services through its Medical Center in Paris, and technology transfer including the €20.7M-seed-funded spinout Enodia Therapeutics. Its go-to-market is community-led and event-driven, engaging the Pasteur Network, Open Science initiatives, and European research partnerships. Recent strategic actions include a landmark skin microbiome research partnership with L'Oréal (December 2025), expansion of African clinical trial capacity through ACT-CHIK, and the launch of the Pasteur 2030 strategic plan under President Yasmine Belkaid and Director General Stewart Cole.

The institute serves three primary constituencies: the general public through its Medical Center's consultations and vaccinations; the global scientific research community through collaborative programs and training; and public health organizations including WHO and national ministries of health. Secondary segments include healthcare/beauty industry partners such as L'Oréal and Johnson & Johnson, and pharmaceutical investors participating in Pasteur-derived spinouts. Notable recent recognition includes Anne Dejean's 2026 Shaw Prize in Life Science and Medicine for leukemia research.

Name

Pasteur Institute

Legal name

Institut Pasteur

Website

https://pasteur.fr

Company type

Private

Founded year

1887

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

The Pasteur Institute is a French non-profit biomedical research foundation founded in 1887, conducting infectious disease, immunology, and antimicrobial resistance research across 133 Paris-based units and a global network of 30+ member institutes, while serving public health agencies, the scientific community, and the general public.

Ownership category

akta.pro rank

Product category

Biomedical Research

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Global Health Research, Clinical Trials & Product Development Partnerships (PDPs) (HLAJAOAM)

Keywords

• Infectious disease research
• Biomedical research services
• Vaccine development
• Public health surveillance
• Clinical medical services

Headquarters

HQ city

Paris

HQ country

France

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure

Revenue model

1. Research Funding and Grants: Government and international research funding for scientific programs including European partnerships, public health initiatives, and infectious disease research.
2. Medical Center Services: Clinical services including consultations, vaccinations, and travel medicine provided through the Centre Médical de l'Institut Pasteur.
3. Donations and Philanthropy: Public donations through PasteurDon campaigns, corporate partnerships, and foundation support including the Bettencourt Schueller Foundation.
4. Technology Transfer: Innovation and technology transfer through spinouts like Enodia Therapeutics and industrial partnerships for vaccine development and diagnostics.

Go-to-market motion2 records

Distribution channels5 records

Marketing channels10 records

Core offering

The Pasteur Institute is a French non-profit biomedical research foundation that conducts fundamental and applied research in infectious diseases, immunology, microbiology, and genomics. It operates a Medical Center (Centre Médical) in Paris providing clinical consultations, vaccinations, and travel health services, and runs the Pasteur Network of 32+ member institutes coordinating global infectious disease surveillance and outbreak response.

Product overview

Institut Pasteur is a renowned French biomedical research institution with four core missions: research, health, education, and innovation/technology transfer. The organization operates a Medical Center offering clinical services including consultations and vaccinations, maintains the Pasteur Network of 32 international institutes, and conducts extensive research across infectious diseases, microbiology, and immunology. Research outputs include vaccine candidates (such as MV-CHIK for chikungunya), microfluidic diagnostic tools (spleen-on-a-chip), and AI-powered vector identification applications. The institution also provides Open Science training through the OpenPlato platform and operates specialized research facilities including the Center for Vector-Borne Diseases.

Differentiator

Problem solved

Functional benefit

Products and services

• Medical Center (Centre médical) Clinical facility providing consultations, vaccinations, travel health advice, and disease information sheets to individual patients and travelers in Paris.
• Pasteur Network International network of 32+ institutes enabling coordinated research, surveillance, training, and outbreak response to infectious diseases worldwide.
• Collection de l'Institut Pasteur (CIP) Biological resource center housing over 25,000 bacterial strains across 5,500 species, including a unique resistant strain collection that supports antimicrobial resistance research.
• OpenPlato E-Learning Platform E-learning platform used for Open Science training activities covering Open Access publishing and FAIR data management.
• MV-CHIK Chikungunya Vaccine Candidate Vaccine candidate advancing through Phase Ib/III clinical trials in Rwanda, Kenya, Nigeria, and Senegal under the ACT-CHIK €15.3 million project.

Quantifiable outcome

• 150% higher cancer risk in high pesticide exposure areas
• +3 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

18 partnerships are on record, tiered core, major and minor.

• OpenAIREcoreStrategic or Co-development Partner · 20 April 2026Strategic collaboration through Memorandum of Understanding for Open Science training and research capacity strengthening across Europe. Joint design and delivery of training activities using OpenPlato's e-learning platform, focusing on Open Access publishing, FAIR data management, and responsible research practices. Collaboration aims to foster participation in European research projects and strengthen connections between OpenAIRE network and Pasteur Network of 30+ institutes worldwide.
• L'OréalcoreStrategic or Co-development Partner · 16 December 2025Historic research partnership combining L'Oréal's expertise in advanced beauty skin science with Institut Pasteur's leadership in immunology, microbiology, and skin biomarkers research. Focus on studying skin microbiome, immune responses, and biological markers to understand skin's role in overall health. Formalized on December 16, 2025 at L'Oréal's Advanced Research center in Aulnay-sous-Bois.
• European Molecular Biology Laboratory (EMBL)coreStrategic or Co-development PartnerStrategic collaboration funded by over €1 million to promote research in infection biology across Europe. Includes projects on bacterial infections, antibiotic resistance, and antivirals, as well as training programs for early-career scientists and development of Center for Vector-Borne Diseases.
• Johnson & Johnson Innovative Medicine Research & DevelopmentmajorStrategic or Co-development PartnerCollaboration on inflammatory disease research, with Institut Pasteur contributing expertise in immunology and microbiology to improve understanding of immune system and advance therapies for chronic inflammatory conditions.
• Enodia TherapeuticscoreStrategic or Co-development PartnerStartup spun out from Institut Pasteur launched in February 2025, based on research by Caroline Demangel's immunobiology and therapy unit. Sec61 translocon-modulating platform for treating autoimmune and inflammatory diseases. Institut Pasteur participated as investor in €20.7 million seed funding round.
• Institut Pasteur de DakarcoreStrategic or Co-development PartnerTechnology transfer partner for chikungunya vaccine manufacturing in Africa through ACT-CHIK project, supporting local vaccine production capacity in Africa.
• Fred Hutchinson Cancer CenterminorStrategic or Co-development PartnerResearch collaboration partner in coronavirus Orf9b protein study discovering molecular signatures that predict viral spillover potential from bats to humans.
• MITminorStrategic or Co-development PartnerCollaborative development of spleen-on-a-chip microfluidic device for studying sickle cell disease, along with Nanyang Technological University and Brown University.
• InsermmajorStrategic or Co-development PartnerJoint research with Institut Pasteur on food emulsifier impact during pregnancy and breastfeeding, studying effects on offspring gut microbiome and immune response.
• Université Paris CitécoreStrategic or Co-development PartnerPartner in UK-France Strategic Biomedical Alliance in Health and AI announced at G7 Digital and Technology Ministerial Summit, focusing on women's health research including childbirth complications and endometriosis.
• Diamond Light SourcemajorStrategic or Co-development PartnerPartner in UK-France Strategic Biomedical Alliance, contributing advanced imaging capabilities for women's health research using AI.
• Synchrotron SoleilmajorStrategic or Co-development PartnerPartner in UK-France Strategic Biomedical Alliance for advanced imaging research in women's health using synchrotron technology and AI.
• Imperial College LondonmajorStrategic or Co-development PartnerSeparate agreement with France's National Center for Scientific Research (CNRS) for metabolism research targeting heart disease, cancer, and neurodegenerative disorders.
• Université Paris CitéminorStrategic or Co-development PartnerInternational research partner in UPFront project studying ultra-processed foods and colorectal cancer risk, funded by Canadian Cancer Society and CIHR.
• Institut de Recherche pour le Développement (IRD)majorStrategic or Co-development PartnerResearch collaboration on pesticide dispersion modeling and cancer risk assessment in Peru, combined with data from over 150,000 cancer patients.
• Université de ToulouseminorStrategic or Co-development PartnerAcademic partner in study published in Nature Health on association between pesticide exposure and increased cancer risk.
• Peru's National Institute of Neoplastic DiseasesminorStrategic or Co-development PartnerResearch collaboration on cancer patient data (2007-2020) combined with pesticide dispersion modeling (2014-2019) for environmental health risk assessment.
• Argobio StudiocoreStrategic or Co-development PartnerCompany creator that spun out Enodia Therapeutics from Institut Pasteur based on research of co-founder Caroline Demangel.

Scale indicators13 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Broad Institute of MIT and Harvard: US-based biomedical and genomic research institute. Direct peer — comparable scope of infectious disease, genomics, and therapeutic research with strong university affiliation, major philanthropic backing, and active spinout/technology-transfer activity.
• Max Planck Institute for Infection Biology: Germany's premier infection biology research institute. Direct peer — both are national biomedical research foundations specializing in infectious diseases, immunology, and microbiology with global scientific standing and government-grant-driven funding models.
• Scripps Research Institute: US-based nonprofit biomedical research organization. Direct peer — similar nonprofit research structure, focus on immunology and infectious diseases, history of drug discovery spinouts, and academic-industrial partnerships.
• Karolinska Institutet: Sweden's leading medical university with deep infectious disease and immunology research programs. Direct peer — Nordic peer with similar scientific scope, Nobel Prize lineage, and government-grant funding model.
• Wellcome Sanger Institute: UK-based genomic and infectious disease research institute funded by the Wellcome Trust. Direct peer — comparable scale, genomic and pathogen surveillance focus, and large-scale public-good research mission with parallel global health mandate.
• Francis Crick Institute: UK's flagship biomedical discovery institute with ~1,500 scientists. Direct peer — analogous scale and scope of biomedical research with strong public funding base, government charter, and industrial partnership approach.

Regional players

• Walter Reed Army Institute of Research: US Department of Defense biomedical research laboratory focused on infectious diseases and vaccine development. Regional peer — operates in the same infectious-disease and vaccine-development space but with military/government focus and US geographic base.

Broad incumbents

• Howard Hughes Medical Institute: US-based biomedical research organization with $20B+ endowment supporting ~300 investigators. Broad incumbent — significantly larger scale but analogous mission of advancing biomedical research through investigator-driven science and institutional support.
• National Institutes of Health (NIH): US federal agency conducting and funding biomedical research with $45B+ annual budget. Broad incumbent — vastly larger scale but defines the global biomedical research funding ecosystem that Pasteur operates within, and serves overlapping scientific communities.

Others

• Coalition for Epidemic Preparedness Innovations (CEPI): Global partnership funding vaccine development against epidemic threats. Adjacent peer — not a direct competitor but a key funding/coordination partner in the same global-health ecosystem for vaccine R&D that Pasteur participates in via ACT-CHIK and similar projects.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/user/institutpasteurvideo
• Facebookfacebook.com/InstitutPasteur
• LinkedInlinkedin.com/company/10849
• Instagraminstagram.com/institut.pasteur
• Xx.com/aiderpasteur

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pasteur Institute